油醇聚醚-2 | 5274-65-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 油醇聚醚-2
• 英文名称: POE-(2)-oleylalkohol
• 英文别名: (Z)-3,6-dioxatetracos-15-en-1-ol；oleth-2；Genapol O020；Brij92；2-(2-octadec-9c-enyloxy-ethoxy)-ethanol；brij 93；2-[2-[(Z)-octadec-9-enoxy]ethoxy]ethanol
• CAS: 5274-65-7
• 化学式: C₂₂H₄₄O₃
• 分子量: 356.59
• InChiKey: MGYUQZIGNZFZJS-KTKRTIGZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.3
• 重原子数：
  25
• 可旋转键数：
  21
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  38.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  油醇聚醚-2 在 二乙胺基三氟化硫 作用下， 以 二氯甲烷 为溶剂， 以34%的产率得到(Z)-1-fluoro-3,6-dioxatetracos-15-ene
  参考文献：
  名称：

  Novel Amphiphilic Probes for [¹⁸F]-Radiolabeling Preformed Liposomes and Determination of Liposomal Trafficking by Positron Emission Tomography

  摘要：

  Positron-emission tomography (PET) is a noninvasive realtime functional imaging system and is expected to be useful for the development of new drug candidates in clinical trials. For its application with preformulated liposomes, we devised an optimized [F-18]-compound and developed a direct liposome modification method that we termed the "solid-phase transition method". We were successful in using 1-[F-18]fluoro-3,6-dioxatetracosane ([F-18]7a) for in vivo trafficking of liposomes. This method might be a useful tool in preclinical and clinical studies of lipidic particle-related drugs.

  DOI：

  10.1021/jm7010518
• 作为产物：
  描述：

  二乙二醇 、 油酰氯 生成 油醇聚醚-2
  参考文献：
  名称：

  HOZUMI, MOTOO;NOMURA, HIROAKI;YOSHIOKA, YOSHIO

  摘要：

  DOI：

文献信息

• Low dusting crystal transformations of 2,2'-methylenbis[4-(1,1,3,3-tetramethylbutyl)-6-benzotriazolylphenol] and mixture thereof, method for preparing them, and ultraviolet absorbent using the same
  申请人：——

  公开号：US20040242733A1

  公开（公告）日：2004-12-02

  The present invention relates to a low dusting crystalline 2,2′-methylenebis[4-(1,1,3,3-tetramethylbutyl)-6-benzotriazolylphenol] type I crystal transformation which exhibits diffraction peaks at diffraction angles (2&thgr;±0.1°) of 7.1°, 8.6°, 14.3°, 16.1°, 18.1° and 23.0° in powder X-ray diffraction analysis with Cu-K&agr; radiation; a low dusting 2,2′-methylenebis[4-(1,1,3,3-tetramethylbutyl)-6-benzotriazolylphenol] type II crystal transformation which does not exhibit a distinct diffraction peak but an amorphous halo in powder X-ray diffraction analysis with Cu-K&agr; radiation; a mixture thereof; a method for preparing them; and a UV light absorber, an emulsion composition and a polymer material using them.

  本发明涉及一种低粉尘结晶2,2'-亚甲基双[4-(1,1,3,3-四甲基丁基)-6-苯并三唑基苯酚]I型晶体转化，该晶体在Cu-K&agr;辐射下的粉末X射线衍射分析中表现出在衍射角度(2&thgr;±0.1°)为7.1°、8.6°、14.3°、16.1°、18.1°和23.0°的衍射峰；一种低粉尘2,2'-亚甲基双[4-(1,1,3,3-四甲基丁基)-6-苯并三唑基苯酚]II型晶体转化，其在Cu-K&agr;辐射下的粉末X射线衍射分析中不表现出明显的衍射峰，而是呈现出无定形的晕影；以及它们的混合物、制备它们的方法以及使用它们的UV光吸收剂、乳液组合物和聚合物材料。
• 2-(Amino or substituted amino)-5-(substituted oxymethyl)-phenol compounds, dyeing compositions containing them, and use thereof
  申请人：Lim Muill

  公开号：US20050005370A1

  公开（公告）日：2005-01-13

  Disclosed are 2-(amino or substituted amino)-5-(substituted oxymethyl)-phenol compounds according to the Formula (I), as defined herein. Also, compositions for the oxidative dyeing of keratin fibers, comprising a medium suitable for dyeing and a compound of the Formula (II), as defined herein. The substituents of both formulae may themselves be substituted or unsubstituted. Further, methods for oxidative dyeing of keratin fibers, comprising applying such compositions in the presence of an oxidizing agent, for a period which is sufficient to develop the desired coloration.

  本发明涉及以下式（I）所定义的2-（氨基或取代氨基）-5-（取代氧甲基）-酚化合物。此外，本发明还涉及一种用于角蛋白纤维氧化染色的组合物，包括适用于染色的介质和本发明所定义的式（II）的化合物。两个公式的取代基本身可以被取代或未取代。此外，本发明还涉及一种氧化染色角蛋白纤维的方法，包括在氧化剂存在下应用这样的组合物，以便发展所需的染色。
• 2-(amino or substituted amino)-5-(substituted oxymethyl)-phenol compounds, dyeing compositions containing them, and use thereof
  申请人：The Procter & Gamble Company

  公开号：US07226487B2

  公开（公告）日：2007-06-05

  Disclosed are 2-(amino or substituted amino)-5-(substituted oxymethyl)-phenol compounds according to the Formula (I), as defined herein. Also, compositions for the oxidative dyeing of keratin fibers, comprising a medium suitable for dyeing and a compound of the Formula (II), as defined herein. The substituents of both formulae may themselves be substituted or unsubstituted. Further, methods for oxidative dyeing of keratin fibers, comprising applying such compositions in the presence of an oxidizing agent, for a period which is sufficient to develop the desired coloration.

  本发明涉及一种公式（I）所定义的2-（氨基或取代氨基）-5-（取代氧甲基）-苯酚化合物。此外，本发明还涉及一种用于角蛋白纤维氧化染色的组合物，该组合物包括适用于染色的介质和公式（II）所定义的化合物。两个公式的取代基本身可以被取代或未取代。此外，本发明还涉及一种角蛋白纤维氧化染色的方法，包括在氧化剂存在下应用这样的组合物，时间足以发展所需的着色。
• Ethylene glycol derivatives of ammonioethyl phosphate, their production and use
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP0040039A1

  公开（公告）日：1981-11-18

  New ethylene glycol derivatives, inclusive of salts thereof, which have the formula: wherein n is an integer of 1 to 15; R1 is an aliphatic hydrocarbon group containing 6 to 26 carbon atoms; R2 R3 and R4 are independently H or lower alkyl, or represents a cyclic ammonio group, exhibit inhibitory activity to multiplication of tumor cells and antimicrobial activity.

  新的乙二醇衍生物，包括其盐类，其式如下 其中 n 是 1 至 15 的整数；R1 是含有 6 至 26 个碳原子的脂肪族烃基；R2 R3 和 R4 独立地是 H 或低级烷基，或 代表环氨基团，具有抑制肿瘤细胞繁殖的活性和抗菌活性。
• Estradiol transdermal delivery system
  申请人：PACO PHARMACEUTICAL SERVICES

  公开号：EP0328806A2

  公开（公告）日：1989-08-23

  The present invention is directed to a transdermal delivery system (10) for an active substance. The active substance is estrogen or its derivatives and preferably is 17-beta-estradiol. The system (10) comprises an impermeable backing layer (12) and a matrix (14) affixed thereto. The matrix (14) comprises, on a weight percentage basis, from about 60 to about 95% of an adhesive polymer, from about 5 to about 20% of a solvent, from about 0.2 to about 4% of a skin penetration enhancer, and from about 0.5 to about 5% of the active substance. The system is free of any discrete permeable, polymeric, diffusion-controlling membrane.

  本发明涉及一种活性物质透皮给药系统（10）。活性物质是雌激素或其衍生物，最好是 17-beta-雌二醇。该系统（10）包括一个防渗背层（12）和一个贴在其上的基质（14）。按重量百分比计算，基质（14）包括约 60%至约 95%的粘合聚合物、约 5%至约 20%的溶剂、约 0.2%至约 4%的皮肤渗透增强剂和约 0.5%至约 5%的活性物质。该系统不含任何离散渗透性聚合物扩散控制膜。